Adoption and Implementation of Medications in Addiction Treatment Programs

Objectives:Little is known about the extent to which medications are being implemented as routine care in addiction treatment programs. This research describes medication adoption and implementation within the privately funded treatment sector. Methods:Face-to-face interviews were conducted with 345 administrators of a nationally representative sample of privately funded substance treatment organizations in the United States. Results:Rates of adoption of addiction treatment medications in private sector programs were lower than the adoption of psychiatric medications. Even when analyses were restricted to programs with access to physicians, adoption of each addiction treatment medication had occurred in less than 50% of programs. Within adopting programs, implementation was highly variable. Although approximately 70% of patients with cooccurring psychiatric diagnoses received psychiatric medications, rates of implementation of medication-assisted treatment for opioid dependence and alcohol use disorders were just 34.4% and 24.0%, respectively. Conclusions:Although previous research has documented higher rates of medication adoption in privately funded treatment programs, this study revealed that both adoption and implementation of pharmacotherapies to treat addiction remains modest. Future research should examine the different types of barriers to implementation, such as physician decision making, patient preferences, and system-level barriers stemming from financing and public policy.

[1]  Alison L. Koch,et al.  Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. , 2006, Drug and alcohol dependence.

[2]  Lori J. Ducharme,et al.  State policy influence on the early diffusion of buprenorphine in community treatment programs , 2008, Substance abuse treatment, prevention, and policy.

[3]  W. Kissin,et al.  Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence , 2006, Journal of addictive diseases.

[4]  Dennis McCarty,et al.  Research to practice: adoption of naltrexone in alcoholism treatment. , 2003, Journal of substance abuse treatment.

[5]  T. Mark,et al.  Understanding US addiction physicians' low rate of naltrexone prescription. , 2003, Drug and alcohol dependence.

[6]  N. Brown,et al.  Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. , 2004 .

[7]  W. Ling,et al.  Medications development: successes and challenges. , 2005, Pharmacology & therapeutics.

[8]  C. Thomas,et al.  Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. , 2008, Psychiatric services.

[9]  D. McCarty,et al.  Client and counselor attitudes toward the use of medications for treatment of opioid dependence. , 2007, Journal of substance abuse treatment.

[10]  Lori J. Ducharme,et al.  Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. , 2006, Journal of substance abuse treatment.

[11]  Lori J. Ducharme,et al.  The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. , 2007, Drug and alcohol dependence.

[12]  John Fitzgerald,et al.  Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach. , 2009, Psychological services.

[13]  J. Chilingerian,et al.  Substance Abuse Treatment Organizations as Mediators of Social Policy: Slowing the Adoption of a Congressionally Approved Medication , 2008, The Journal of Behavioral Health Services & Research.

[14]  Lori J. Ducharme,et al.  The Use of Antidepressant Medications in Substance Abuse Treatment: The Public-Private Distinction, Organizational Compatibility, and the Environment∗ , 2007, Journal of health and social behavior.

[15]  C. Thomas,et al.  Factors Determining How Early Adopter Physicians Use Buprenorphine in Treatment , 2007, Journal of addiction medicine.

[16]  Lori J. Ducharme,et al.  Counselor attitudes toward pharmacotherapies for alcohol dependence. , 2009, Journal of studies on alcohol and drugs.

[17]  T. Mark,et al.  Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications. , 2003, Value in Health.

[18]  Lori J. Ducharme,et al.  Organizational Predictors of Pharmacological Innovation Adoption: The Case of Disulfiram , 2005 .

[19]  Carolyn J. Heinrich,et al.  Role of state policies in the adoption of naltrexone for substance abuse treatment. , 2007, Health services research.

[20]  Joffre Swait,et al.  Using stated preference and revealed preference modeling to evaluate prescribing decisions. , 2004, Health economics.

[21]  Lori J. Ducharme,et al.  Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. , 2005, Journal of substance abuse treatment.

[22]  C. Horgan,et al.  Availability of addiction medications in private health plans. , 2008, Journal of substance abuse treatment.

[23]  Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. , 2009, Journal of substance abuse treatment.

[24]  Adoption of naltrexone to treat alcohol dependence. , 2005, Journal of substance abuse treatment.

[25]  Lori J. Ducharme,et al.  Trends in the Adoption of Medications for Alcohol Dependence , 2006, Journal of clinical psychopharmacology.

[26]  P. Friedmann,et al.  Top Manager Effects on Buprenorphine Adoption in Outpatient Substance Abuse Treatment Programs , 2010, The Journal of Behavioral Health Services & Research.

[27]  Lori J. Ducharme,et al.  Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. , 2007, Journal of substance abuse treatment.

[28]  H. Knudsen,et al.  Modeling the use of innovations in private treatment organizations: the role of absorptive capacity. , 2004, Journal of substance abuse treatment.

[29]  P. Roman,et al.  Adoption and implementation of new technologies in substance abuse treatment. , 2002, Journal of substance abuse treatment.

[30]  C. Cunningham,et al.  Factors affecting willingness to provide buprenorphine treatment. , 2009, Journal of substance abuse treatment.